154 results
8-K
EX-99.1
ELOX
Eloxx Pharmaceuticals, Inc.
13 Nov 23
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
4:58pm
, we received a delisting determination from the Listing Qualifications Department of the Nasdaq Stock Market LLC as the company did not regain
8-K
ELOX
Eloxx Pharmaceuticals, Inc.
16 Oct 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:26pm
Notification”) from the staff (the “Staff”) of the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that Nasdaq
8-K
EX-1.1
l1tw 9m05q
24 May 23
Entry into a Material Definitive Agreement
8:07am
8-K
wfr v8lwv
14 Apr 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:06pm
8-K
p83 zxyozg
14 Oct 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:31pm
8-K
EX-99.1
iu723 vl0or
5 Jul 22
Eloxx Pharmaceuticals Announces Changes to Board of Directors
8:28am
8-K
4bf2p
5 Jan 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K
EX-99.2
2ybqx07q0z hxfvnt4v6
17 Nov 21
Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients
7:41am